PR Newswire
- Kytopen and Bio-Techne announce partnership on an integrated cellular engineering workflow to expedite cell therapy manufacturing.
- The TcBuster™ system offers a fast and scalable method to integrate large, multigene cargos with high editing efficiency in a single vector, while Flowfect ® continuous flow technology enables the gentle, high-efficiency processing of billions of cells in minutes.
- The companies' combined technologies deliver high gene insertion efficiencies and high cell viabilities, enabling a non-viral gene-editing workflow ideal for the development of advanced cell therapies.
- The data will be presented in a poster at ISCT, May 7-10, 2025 , in New Orleans .
CAMBRIDGE, Mass. and MINNEAPOLIS , May 8, 2025 /PRNewswire/ -- Kytopen Corp., a leader in providing continuous flow cellular engineering technologies and Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative life science research tools today announced a partnership aimed at streamlining gene delivery solutions for the development and manufacture of advanced cell therapies. The collaboration will focus on the synergies developers can achieve by utilizing the TcBuster™ GMP non-viral genome engineering system and the Flowfect Tx™ GMP cellular engineering platform. Together, these technologies offer a clear path to shortened workflows for generating more efficient genome engineering of immune cell therapies, expediting their advancement to clinical stages and subsequent manufacturing.
Non-viral TcBuster offers numerous benefits over traditional lentivirus-based engineering methods. The hyperactive TcBuster transposase enables delivery of multiple genes simultaneously while maintaining high editing efficiency and a de-risked insertional profile. Flowfect ® technology is a highly tunable system. It is unique in that it combines mechanical, electrical, and chemical forces, and allows the adjustment of multiple parameters to maximize transfection efficiency, cell health, and cell yield, while continuous flow enables the processing of hundreds of billions of healthy, high-quality engineered cells in just minutes. Together these technologies provide a streamlined gene delivery process that can achieve therapeutic doses quicker.
"We are excited about the opportunity to work with such a reputable life science provider as Bio-Techne", said Kevin Gutshall , Chief Commercial Officer at Kytopen, "Together our technologies offer a non-viral, gene-editing platform suitable for a range of immune cell types, in particular non-dividing cells and those sensitive to apoptosis, that will enable developers to bring more effective, advanced cell therapies to market quicker."
Data generated through the collaboration will be presented at the International Society of Cell & Gene Therapy (ISCT) Annual Meeting, May 7-10, 2025 , in New Orleans , USA . The data will also be featured in Kytopen's Global Showcase Oral Presentation on Thursday, May 8, 2025 , at 6:00pm . For more information at ISCT, the Kytopen and Bio-techne teams will be available to answer any questions at booths 347 and booth 932, respectively.
ISCT Poster Presentation. Wednesday, May 7, 2025 , at 6:00pm ; POSTER BOARD: 1105
CONTINUOUS FLOW TRANSFECTION WITH FLOWFECT ® TECHNOLOGY AS AN EFFICIENT, NON-VIRAL TECHNOLOGY FOR SCALABLE CRISPR-MEDIATED ENGINEERING OF PRIMARY T CELLS
Global Showcase. 15 min Presentation, Thursday, May 8, 2025 , at 6:00pm
A FULLY VALIDATED, NON-VIRAL GMP PLATFORM FOR THE MANUFACTURE OF ENGINEERED CELLS AT CLINICAL AND COMMERCIAL SCALE
For further information:
Kytopen:
Investor Contact:
Michael Chiu PhD., CEO
mchiu@kytopen.com
Business and Corporate Development Contact:
Kevin Gutshall , CCO
kgutshall@kytopen.com
About Kytopen:
The innovative leader in non-viral, continuous flow cellular engineering technologies, Kytopen, headquartered in Cambridge, Massachusetts , is transforming how cell therapies are manufactured by maximizing yields, delivering hundreds of billions of engineered cells in minutes – faster than any other technology – and thereby accelerating the discovery, development, and manufacture of advanced engineered cell therapies. Its Flowfect ® cellular engineering technology is highly tunable, gentle on cells, and has demonstrated performance across a range of cell types, payloads, and therapeutic applications. Kytopen has recently disclosed strategic partnerships with industry-leading biotechnology companies, contract development and manufacturing organizations (CDMOs), and cell therapy-focused medical centers. Kytopen continues to engage strategic partners and is committed to enabling their partners' success by providing innovative technology and developing close collaborative relationships to bring lifesaving, next generation cell therapies to patients worldwide. www.kytopen.com
Bio-Techne
David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit http://www.bio-techne.com or follow the Company on social media at Facebook , LinkedIn , Twitter or YouTube .
SOURCE Kytopen
MWN AI FAQ **
** MWN AI Questions are based on asking OpenAI to ask and answer four questions about this news release.
